Abstract
The selective cytocidal effect of alkyl lysophospholipids against neoplastic cells while sparing normal cells make these ideal candidates for purging leukemic cells from bone marrows obtained during remission. To test the feasibility of such an approach, a murine model and an in vitro human cell model were developed. In the murine system a mixture of normal bone marrow cells and WEHI IIIB myelomonocytic leukemic cells was incubated with varying doses of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-Me) for 24 hr before being injected into tail veins of lethally irradiated Balb/c mice. At doses of 20 and 100 μg/ml, long-term survivors were noted. The additional steps of freezing and thawing following incubation resulted in significantly longer survival with doses of 10 to 50 μg/ml, but were toxic to marrow stem cells at 100 μg/ml.
In the in vitro model, normal marrow progenitor cells and leukemic cells (the promyelocytic cell line HL60) were exposed to varying concentrations of ET-Me for 1 and 4 hr alone or mixed, and clonogenicity was assayed by colony formation in semisolid medium during 7–14 days’ incubation. At doses up to 100 μg/ml exposed for 4 hr normal progenitor cells were spared and HL60 colonies eliminated. Other phospholipids analogues were less effective in eliminating leukemic cells, but spared normal progenitor cells.
A survey of fresh leukemic cells found varying degrees of sensitivity to ET-Me, indicating the need for testing a variety of compounds.
These studies clearly indicated the potential usefulness of alkyl lysophospholipid compounds in selectively purging leukemic cells from remission marrows for autologous bone marrow transplantation.
Similar content being viewed by others
Abbreviations
- ALP:
-
alkyl lysophospholipid
- CFU-S:
-
colony forming units spleen
- CP:
-
4-aminomethyl-1-[2,3-(di-n-decycloxy)-n-propyl]-4-phenylpiperidine dihydrochloride
- ET-Ac:
-
1-O-hexadecyl-2-acetamidodeoxyglycero-phosphocholine
- ET-Me:
-
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
- FBS:
-
fetal bovine serum
- LC:
-
leukemic
- NBM:
-
normal bone marrow
- RPMI:
-
Roswell Park Memorial Institute
- SRM:
-
simulated remission marrow
- TBI:
-
total body irradiation
References
Andreesen, R., Modolell, M., Weltzien, H.U., Eibl, H., Common, H.H., Lohr, G.W., and Munder, P.G. (1978)Cancer Res. 38, 3894–3899.
Andreesen, R., Modolell, M., and Munder, P.G. (1979)Blood 54, 519–523.
Modolell, M., Andreesen, R., Pahlke, W., Brugger, U., and Munder, P.G. (1979)Cancer Res. 39, 4681–4686.
Tarnowski, G.S., Mountain, I.M., Stock, C.C., Munder, P.G., Weltzien, H.U., and Westphal, O. (1978)Cancer Res. 38, 339–344.
Berdel, W.E., Bausert, W.R., Weltzien, H.U., Modolell, M.L., Widmann, K.H., and Munder, P.G. (1980)Eur. J. Cancer 16, 1199–1204.
Runge, M.G., Andreesen, R., Pfleiderer, A., and Mumder, P.G. (1980)J. Natl. Career Inst. 64, 1301–1306.
Berdel, W.E., Fink, U., Egger, B., Reichert, A., Munder, P.G., and Rastetter, J. (1981)J. Cancer Res. Clin. Oncol. 101, 325–330.
Berdel, W.E., Greiner, E., Fink, U., Zanker, K.S., Stravrou, D., Trappe, A., Fahlbusch, R., Reichert, A., and Rastetter, J. (1984)Oncology 41, 140–145.
Berdel, W.E., Schlehe, H., Fink, U., Emmerich, B., Maubach, P.A., Emslander, H.P., Daum, S., and Rastetter, J. (1982)Cancer 50, 2011–2015.
Soodsma, J.F., Piantadosi, C., and Synder, F. (1970)Cancer Res. 30, 309–311.
Snyder, F., Malone, B., and Piantadosi, C. (1973)Biochim. Biophys. Acta 316, 259–265.
Berdel, W.E., Fromm, M., Fink, U., Pahlke, W., Bicker, U., Reichert, A., and Rastetter, J. (1983)Cancer Res. 43, 5538–5543.
Unger, C., Eibl, H., von Heyden, H.W., and Nagel, G.A. (1985)Cancer Res. 45, 616–618.
Glasser, L., Somberg, L.B., and Vogler, W.R. (1984)Blood 64, 1288–1291.
Vogler, W.R., Whigham, E., Bennett, W.D., Olson, A.C. (1985)Exp. Hematol. 13, 629–633.
Okamoto, S., Olson, A.C., Vogler, W.R., and Winton, E.F.,Blood 69, 1381–1387.
Wolff, J.S. III, Hemsworth, G.R., Kraska, A.R., Hoffman, W.W., Figdor, S.K., Fisher, D.O., Jakowski, R.M., Niblack, J.F., and Jensen, K.E. (1982)Cancer Immunol. Immunother. 12, 97–103.
Warner, N.L., Moore, M.A., and Metcalf, D. (1969)J. Natl. Cancer Inst. 43, 963–982.
Collins, S.J., Gallo, R.C., and Gallagher, R.E. (1977)Nature 270, 347–349.
Tidwell, T., Guzman, G., and Vogler, W.R. (1981)Blood 57, 794–797.
Fauser, A.A., and Messner, H.A. (1979)Blood 54, 1197–1200.
Burgess, A.W., Wilson, E.M.A., and Metcalf, D. (1977)Blood 49, 573–585.
Munder, P.G., Gerber, E., Modolell, M., and Fischer, H. (1969)Int. Arch. Allergy Appl. Immunol. 36, 117–128.
Munder, P.G., and Modolell, M. (1973)Int. Arch. Allergy Appl. Immunol. 45, 133–135.
Author information
Authors and Affiliations
About this article
Cite this article
Vogler, W.R., Olson, A.C., Okamoto, S. et al. Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation. Lipids 22, 919–924 (1987). https://doi.org/10.1007/BF02535555
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535555